Pulmonx Corporation (LUNG) investor relations documents from the company's IR site: 1 presentation, 9 press releases; latest deck 2026-07-29. Read in-app with summaries. First-party data.
Pulmonx Investor Presentation – July 2026 — Pulmonx provides the Zephyr Valve system for minimally invasive emphysema treatment, addressing a $12B market with established global reimbursement and clinical efficacy.
| Published | Type | Document |
|---|---|---|
| 2026-07-29 | Presentation | Pulmonx Investor Presentation – July 2026 |
| 2026-07-29 | Press release | Pulmonx Reports Second Quarter 2026 Financial Results |
| 2026-07-15 | Press release | Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026 |
| 2026-06-01 | Press release | Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-29 | Press release | Pulmonx Reports First Quarter 2026 Financial Results |
| 2026-04-28 | Press release | Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference |
| 2026-04-15 | Press release | Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026 |
| 2026-03-04 | Press release | Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-04 | Press release | Pulmonx Announces Closing of up to $60 Million Credit Facility |
| 2026-02-20 | Press release | Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 |
LUNG overview · LUNG earnings · LUNG financials · LUNG KPIs · LUNG ownership · LUNG peers · LUNG filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.